BRIEF

Biotech firms in China are seeing an increase in drug-design deals with international partners despite mounting regulatory oversight from the United States. Analysts suggest that the interest in Chinese AI-driven pharmaceutical innovation remains robust even as Washington intensifies scrutiny on cross-border technology transfers. The trend highlights a tension between the global pursuit of rapid medical R&D and growing concerns over national security and data sovereignty.